Truist analyst Richard Newitter lowered the firm's price target on iRhythm to $200 from $215 but keeps a Buy rating on the shares. The company delivered Q4 revenue as preannounced as the beat was fueled by another strong ZioAT quarter and progress with innovative channel partners, the analyst tells investors in a research note. The firm adds however that peers have seen some multiple compresson, which underlies the slight multiple and price target reduction.
